The Persisting Burden of Intracerebral Haemorrhage: Can Effective Treatments Be Found?

Colin B. Josephson, Joseph Frantzi, Neshika Samarasekera, Rustam Al-Shahi Salman*

Division of Clinical Neurosciences, Centre for Clinical Brain Sciences, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom

Introduction

Spontaneous intracerebral haemorrhage (ICH) that is apparently unrelated to trauma or an underlying vascular, neoplastic, or coagulopathic cause has incurred the same global burden over the past quarter of a century [1,2]. During the last decade, spontaneous ICH accounted for ~10% of strokes in high income countries and ~20% of strokes in low and middle income countries, where the one month case fatalities were 25–35% and 30–40%, respectively [3].

The incidence of ICH is higher in Asians [2], and the major risk factors for spontaneous ICH without an identified cause (so-called primary ICH) are male gender, systemic arterial hypertension, excessive alcohol consumption, increasing age, smoking, and diabetes mellitus [4]. However, over the past quarter of a century, the incidence of primary ICH associated with pre-stroke hypertension seems to have declined, whereas there seems to have been an increase associated with antithrombotic use and presumed cerebral amyloid angiopathy in those aged ≥75 years [1]. Whilst primary prevention with antihypertensive medication is probably the most effective strategy to reduce the burden of ICH, could the management of ICH influence outcome?

The outcome after primary ICH seems to be worse than after a bleed secondary to an arteriovenous malformation [5], which justifies thorough investigation for all patients (Table 1). However, there is a shortage of evidence and lack of consensus about who, when, and how to further investigate for a cause underlying ICH [6]. There appears to be a modest association between ICH deep in the brain and hypertension, and between ICH in the lobes of the brain and cerebral amyloid angiopathy [7,8], but these associations by no means rule out the need for further investigation of patients who are likely to survive and benefit from the identification of a treatable underlying cause (Table 1) [9].

Apart from identifying and treating underlying causes of ICH, this review focuses on other strategies to improve outcome, bearing in mind the pathophysiological mechanisms underlying clinical deterioration after ICH. We go on to address the treatments for primary ICH that are supported by randomised controlled trials (RCTs) and those that are not, and discuss which interventions appear to be the most promising in ongoing and future RCTs.

Pathophysiology of Acute ICH

In humans, known pathophysiological mechanisms underlying further clinical deterioration soon after ICH include hydrocephalus, intraventricular extension of ICH, and recurrent ICH [10]; pathological and radiological studies have illuminated additional mechanisms (Figure 1). Human studies performing brain computed tomography within two time windows after ICH onset have documented haematoma expansion (Figure 2)—either due to growth of the original haemorrhage or re-bleeding [11–21]—that is associated with poor outcome [12,16,18,22]. Imaging studies have demonstrated peri-haematomal hypoperfusion within the first week of ICH onset [23,24], but not an “ischaemic penumbra” [25,26]. However, there is evidence of a compensatory reduction in the metabolic rate, or a “metabolic penumbra”, around ICH [25,26], as well as peri-haematomal hyperglycolysis (possibly due to inflammation, excitotoxicity, spreading depression, or seizures) [27]. Perihematomal oedema appears to be vasogenic (plasma-derived) [28], its volume may increase within 24 hours of ICH onset and peak within 14 days [29–31], and it may be caused or exacerbated by thrombin and activated platelets [32,33].

Animal models support the contributions to peri-haematomal oedema made by clot retraction, hydrostatic pressure, enhanced thrombin production, increased blood–brain barrier permeability, and products of erythrocyte lysis (such as haeme oxygenase-mediated liberation of iron from haeme rings) [32,34–37]. ICH in animal models seems to trigger humoral and cellular inflammatory responses: the consequent migration and recruitment of neutrophils and activation of native microglia results in oxidative stress and neuronal necrosis [38,39], cytokines such as tumour necrosis factor α and interleukin 1-β lead to apoptosis [40,41], complement activation causes erythrocyte lysis [42], and matrix metalloproteinases may result in oedema, necrosis, and blood–brain barrier disruption [43].

A better understanding of the pathophysiology of ICH could emerge if the decline in human autopsy rates reverses [44], and if animal models of ICH better represent human ICH [45]. Rodent models of ICH involve either stereotactic intraparenchymal infusion of autologous whole blood [5] which may cause simultaneous...
intraventricular or subarachnoid haemorrhage [46]), or injection of proteolytic bacterial collagenase (which incites a vigorous immune response in excess of that seen in humans [46]), after which very few animals die, which is quite unlike spontaneous ICH in humans [2].

**Summary**

Intracerebral haemorrhage (ICH) accounts for ~10% and ~20% of strokes in high and low-middle income countries, respectively, but ICH incidence and case fatality do not appear to be declining. Evidence supports organised stroke unit care and secondary prevention with blood pressure lowering after ICH. Ongoing randomised controlled trials of treatments that are either intended to limit early ICH growth, reduce perihaeatomatal oedema, or modify other key pathophysiological mechanisms underlying deterioration after acute ICH, offer hope for future improvements in outcome.

**Table 1. Investigations into Common Causes of Secondary Intracerebral Haemorrhage (ICH).**

<table>
<thead>
<tr>
<th>Investigation</th>
<th>Common Causes Identified by the Investigation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Further history from patient and others</td>
<td>Undisclosed trauma, drug use</td>
</tr>
<tr>
<td>Routine laboratory tests*</td>
<td>Vascularitis</td>
</tr>
<tr>
<td>Coagulation studies</td>
<td>Warfarin</td>
</tr>
<tr>
<td>Blood cultures</td>
<td>Neoplasms (primary or secondary)</td>
</tr>
<tr>
<td>Toxicology</td>
<td>Cocaine</td>
</tr>
<tr>
<td>Human chorionic gonadotrophin (hCG)</td>
<td>Pregnancy</td>
</tr>
<tr>
<td>Cerebrospinal fluid analysis*</td>
<td>Vascularitis</td>
</tr>
<tr>
<td>CT, CT angiography, CT venography</td>
<td>Neoplasms (primary or secondary)</td>
</tr>
<tr>
<td>MRI, MR angiography, MR venography</td>
<td>Neoplasms (primary or secondary)</td>
</tr>
<tr>
<td>Cerebral catheter angiography</td>
<td>Intracranial arterial aneurysm</td>
</tr>
<tr>
<td>Neuroradiologist review of brain imaging</td>
<td>All causes whose identification depends on brain imaging</td>
</tr>
</tbody>
</table>

*Full blood count, electrolytes, creatinine, urea, liver function tests, inflammatory markers (ESR/CRP), electrocardiogram, chest radiograph.

**Treatments Shown to Be Beneficial in Humans, Either in a Meta-Analysis of RCTs or in a Single Large RCT**

A Cochrane meta-analysis of 31 RCTs involving 6,936 participants showed that organised inpatient care in stroke units benefits patients with stroke (whether ischaemic or due to ICH) by reducing the odds of death or dependency by 18% [47]. Large observational studies corroborate these findings in patients with ICH [48,49]. Which aspects of organized stroke care, either individually or together, improve outcome in patients with ICH remain to be determined. One small, non-randomised, observational analysis, which was adjusted for some of the known influences on ICH prognosis, found survival after ICH to be better when managed in neuro-intensive care units compared to general intensive care units [50]; RCTs of some of the interventions used in the “black box” of neuro-intensive care (such as acute blood pressure lowering) are underway (see below). Furthermore, the benefits of standard care can be inferred from the effects on clinical outcome of do-not-resuscitate orders in a case-mix adjusted multi-hospital observational study [51], and withdrawal of care in a multivariable analysis at a single hospital [52].

A Cochrane meta-analysis of ten RCTs involving 2,059 participants found a reduction in death or dependence from the neurosurgical evacuation of spontaneous supratentorial ICH (odds ratio [OR] 0.71, 95% confidence interval [CI] 0.58 to 0.88) [53]. However, most of the RCTs included in this meta-analysis were of modest quality, their methods differed, and the largest RCT (Surgical Trial in Intracerebral Hemorrhage [STICH]) found no difference between early surgery or initial conservative management [54]. A sub-group with lobar ICH within 1 cm of the cortical surface appeared to benefit from surgery in STICH, so the STICH II RCT (ISRCTN 22153967) is evaluating early ICH evacuation in this sub-group of patients.

Secondary prevention with anti-hypertensive drugs reduced the risk of vascular events after stroke in the PROGRESS RCT; amongst the subset of 611 participants with ICH, the risk of subsequent stroke was halved by a perindopril-based blood pressure lowering regimen [55].

**Treatments Neither Shown to be Beneficial to Humans in a Meta-Analysis of RCTs, Nor in a Single Large RCT**

Haemostatic drugs are a biologically plausible intervention to improve outcome after ICH by limiting the early growth of spontaneous ICH (Figure 2). Despite the ability of recombinant activated factor VIIa (rFVIIa) to curtail early haematoma growth by 4–6 ml, a Cochrane meta-
analysis of four RCTs involving 1,305 participants found that this surrogate outcome did not translate into any net clinical benefit (risk ratio of death or dependence [modified Rankin Scale score 4 to 6] at 90 days = 0.91 [95% CI 0.72 to 1.15]). This reduction in ICH growth may have been too small to improve clinical outcome, its benefit may have been offset by the thrombo-embolic adverse effects of rFVIIa, or the RCTs might have been unable to detect a small benefit of rFVIIa because of insufficient precision or some methodological weaknesses [56]. Other haemostatic drugs including antifibrinolytic agents seem to be worth testing in future RCTs.

Similarly, early blood pressure lowering might improve outcome after ICH by limiting the early growth of spontaneous ICH, but there has been a shortage of evidence supporting this intervention, unsurprisingly leading to differences between ICH guidelines [9,57]. The Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT) randomized 404 patients presenting within 6 hours of onset to a systolic blood pressure target of ≤140 mmHg achieved within 1 hour and continued for 7 days, versus the American Heart Association guideline’s target [9,58]. There was a non-significant reduction in ICH growth by 1–2 ml, and no effect on clinical

Figure 1. Selected pathophysiological mechanisms that have been identified in humans after acute, spontaneous intracerebral haemorrhage. Shapes are approximate illustrations of when pathophysiological mechanisms are at their peak and their known durations. Uncertainties about the duration and intensity of mechanisms are indicated by dashed lines. doi:10.1371/journal.pmed.1000353.g001

Figure 2. Summary of selected radiological studies of spontaneous intracerebral haemorrhage growth. Studies are organised in ascending order of the duration of the time window of the first computed tomogram. Manual calculations of haematoma volume used the ABC/2 method. We excluded data on patients taking anticoagulant drugs in these studies, and excluded studies from which data could not be extracted [77,78], studies that incorporated patients already included in the summary above [79,80], or studies in which interventions may have influenced haematoma growth [58,81]. doi:10.1371/journal.pmed.1000353.g002
outcome, but the safety data are encouraging for the large, ongoing Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT-2; ISRCTN 73916115).

Attenuating peri-haematomal oedema might improve outcome after ICH (Figure 1), but meta-analyses have demonstrated neither benefit nor harm from dexamethasone (five RCTs involving 206 participants) [59], glycerol (two RCTs involving 224 participants) [60], and mannitol (two RCTs involving 149 participants) [61]. Neuroprotection, too, has caused neither benefit nor harm after acute ICH with the anti-oxidant free-radical scavenger NXY-059 (one RCT involving 607 participants) [62] or the glycine antagonist gavestinel (one RCT involving 224 participants) [63].

Future Directions
Attenuation of Haematoma Growth
The major treatment target of ongoing RCTs is haematoma growth, because ICH size and growth are determinants of outcome [12,16,18,22]. So far, the attenuation of early ICH growth seen with the haemostatic agent rFVIIa [56] or intensive acute blood pressure lowering [58,64] has not improved clinical outcome in the RCTs performed. However, this biologically plausible mechanism for improving outcome is worthy of further research in RCTs that are large enough to detect small clinical benefits, such as the ongoing RCTs of acute blood pressure lowering (including INTERACT-2, the Efficacy of Nitric Oxide in Stroke Trial [ENOS; ISRCTN 99414122], Anti-platelet Treatment of Acute Cerebral Haemorrhage II [ATTACH-II; ISRCTN R01-NS044976], and the Scandinavian Candesartan Acute Stroke Trial [SCAST; ISRCTN 13643354]). RCTs of alternative approaches to improve outcome after primary ICH by limiting haematoma expansion include rFVIIa in sub-groups of patients whose haematomas are more likely to grow (The Spot Sign for Predicting and Treating ICH Growth Study [STOP-IT; NCT-00810888]), or testing the effectiveness of antifibrinolytic drugs such as the lysine analogue tranexamic acid, which seems to have attenuated ICH growth in two non-randomised studies [65,66].

The greater risk of haematoma expansion and death after ICH associated with warfarin [67] and the contemporary increase in the incidence of primary ICH associated with all antithrombotic drugs [1] make RCTs of the management of antithrombotic-associated ICH a priority. Whilst stopping warfarin after ICH is common sense, and intravenous vitamin K administration is standard practice, there is a shortage of evidence about how else to treat anticoagulant-associated ICH [68], so RCTs comparing prothrombin complex concentrate with fresh frozen plasma in this context are ongoing (International Normalized Ratio [INR] Normalization in Coumadin Associated Intracerebral Haemorrhage [INCH; NCT00928915] and Efficacy and Safety of BERIPLEX P/N Compared with Plasma in Patients with Acute Major Bleeding Caused by Anticoagulant Therapy [NCT00708435]), as are studies of rFVIIa. The finding that mortality is higher for patients who were on antplatelet agents at the time of ICH compared to those who were not [69] has led to an ongoing RCT of platelet transfusion to limit ICH growth and improve outcome after ICH associated with antplatelet drugs (Platelet Transfusion in Cerebral Haemorrhage [PATCH; http://www.strokecenter.org/trials/TrialDetail.aspx?tid=730]).

Other Approaches
Firstly, targeting other potentially treatable determinants of poor outcome after ICH may be fruitful. Intraventricular extension of ICH is one such mechanism [10], and there are two RCTs of ventricular drainage combined with intraventricular recombinant tissue plasminogen activator (Dutch Intraventricular Thrombolysis after Cerebral Haemorrhage Study [DITCH; ISRCTN 19105863] and Clot Lysis: Evaluation Acceleration of Resolution of IVH [CLEAR-IVH; NCT00630858]); Secondly, just as the PATCH RCT is a response to the apparent rise in incidence of antiplatelet-associated ICH, the apparent rise in the incidence of lobar ICH that may be caused by cerebral amyloid angiopathy merits consideration of treatments that might reduce amyloid deposition [1]. Tramiprosate is a synthetic compound that competes with glycosaminoglycans for binding to β-amyloid peptide, reducing amyloid fibril formation and deposition, and demonstrated a good safety profile in a phase II study [70]. Amyloid-depleting agents, which have shown remarkable effects in Alzheimer’s disease [71], are an alternative approach and may be preferable to amyloid-β immunisation, which can induce an immune-mediated encephalomyelitis [72]. Lastly, treatments that have proven beneficial in animal models might translate from the bench to the bedside, although there are concerns about the rodent ICH models used and the methodological quality of animal experiments [45,46,73]. One such example is deferoxamine (an iron-chelating agent that crosses the blood-brain barrier, and has been associated with a reduction in brain oedema, neurological deficits, and biochemical markers of oxidative damage in animals) [74,75], which has led to the Dose Finding and Safety study of Deferoxamine in Patients with Brain Hemorrhage (DFO in ICH; NCT00598572).

Conclusions
The incidence and risk of dying from ICH seem not to have changed in recent decades, whilst the incidence of ischaemic stroke has declined [2,3]. In contrast to the advances in the treatment of ischaemic stroke, stroke unit care and secondary prevention with blood pressure reduction are the only interventions for patients with stroke due to ICH that are based on robust evidence [47,55]. However, insights gleaned from radiological and pathological investigations of the cause and pathophysiology of ICH, and the relentless pursuit of potential treatments in ongoing RCTs, are all cause for optimism [76].
**Author Contributions**

ICMJE criteria for authorship read and met: CBJ; JF; NS; RASS. Agree with the manuscript’s results and conclusions: CBJ; JF; NS; RASS. Designed the experiments/the study: RASS. Analyzed the data: CBJ; RASS. Collected data/did experiments for the study: CBJ. Wrote the first draft of the paper: CBJ. Contributed to the writing of the paper: CBJ; JF; NS; RASS.

**References**


